Zacks Research Has Bullish Estimate for Docusign Q1 Earnings

Docusign Inc. (NASDAQ:DOCU) – Equities research analysts at Zacks Research upped their Q1 2027 earnings per share (EPS) estimates for Docusign in a note issued to investors on Tuesday, April 7th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.36 for the quarter, up from their previous forecast of $0.32. The consensus estimate for Docusign’s current full-year earnings is $1.17 per share. Zacks Research also issued estimates for Docusign’s Q2 2027 earnings at $0.30 EPS, Q3 2027 earnings at $0.42 EPS, Q4 2027 earnings at $0.45 EPS, FY2027 earnings at $1.53 EPS, Q1 2028 earnings at $0.45 EPS, Q2 2028 earnings at $0.43 EPS, Q3 2028 earnings at $0.41 EPS, Q4 2028 earnings at $0.59 EPS and FY2028 earnings at $1.89 EPS.

Several other equities research analysts have also recently commented on DOCU. BTIG Research reaffirmed a “buy” rating and set a $70.00 target price on shares of Docusign in a research note on Wednesday, March 18th. HSBC set a $53.00 target price on Docusign in a research note on Friday, February 13th. Wells Fargo & Company decreased their target price on Docusign from $75.00 to $60.00 and set an “equal weight” rating for the company in a research note on Wednesday, March 18th. Morgan Stanley decreased their target price on Docusign from $90.00 to $69.00 and set an “equal weight” rating for the company in a research note on Wednesday, March 18th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Docusign in a report on Tuesday, March 10th. Five equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Docusign presently has an average rating of “Hold” and a consensus price target of $64.67.

Docusign Price Performance

NASDAQ DOCU opened at $45.55 on Friday. The business has a 50 day simple moving average of $46.68 and a 200 day simple moving average of $60.81. Docusign has a one year low of $40.16 and a one year high of $94.67. The stock has a market capitalization of $8.86 billion, a P/E ratio of 30.78, a P/E/G ratio of 1.78 and a beta of 0.99.

Docusign (NASDAQ:DOCU) last released its earnings results on Tuesday, March 17th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.95 by $0.06. Docusign had a return on equity of 16.86% and a net margin of 9.60%.The business had revenue of $836.86 million during the quarter, compared to analysts’ expectations of $828.23 million. During the same quarter last year, the firm posted $0.86 earnings per share. The firm’s revenue was up 7.8% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Central Pacific Bank Trust Division bought a new position in shares of Docusign in the fourth quarter valued at approximately $25,000. Modus Advisors LLC bought a new position in shares of Docusign in the fourth quarter valued at approximately $27,000. Torren Management LLC bought a new position in shares of Docusign in the fourth quarter valued at approximately $28,000. Aventura Private Wealth LLC bought a new position in shares of Docusign in the fourth quarter valued at approximately $30,000. Finally, True Wealth Design LLC lifted its holdings in shares of Docusign by 105.2% in the fourth quarter. True Wealth Design LLC now owns 433 shares of the company’s stock valued at $30,000 after purchasing an additional 222 shares in the last quarter. Institutional investors own 77.64% of the company’s stock.

Insiders Place Their Bets

In other Docusign news, insider James P. Shaughnessy sold 12,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $46.83, for a total value of $561,960.00. Following the transaction, the insider owned 53,631 shares in the company, valued at approximately $2,511,539.73. This represents a 18.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CRO Paula Hansen sold 6,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $46.84, for a total value of $281,040.00. Following the completion of the transaction, the executive owned 79,233 shares in the company, valued at approximately $3,711,273.72. The trade was a 7.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 64,673 shares of company stock valued at $3,077,699. 1.01% of the stock is currently owned by corporate insiders.

Docusign declared that its board has authorized a share buyback plan on Tuesday, March 17th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 21% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Key Stories Impacting Docusign

Here are the key news stories impacting Docusign this week:

• Positive Sentiment: Zacks Research lifted its FY2027, FY2028 and FY2029 EPS forecasts materially (FY2027 to $1.53 from $1.24; FY2028 to $1.89 from $1.65; FY2029 to $2.10), signaling improved medium‑term earnings expectations for DOCU. MarketBeat DOCU
• Positive Sentiment: DocuSign’s updated revenue guidance for Q1 2027 ($822M–$826M) and FY2027 (~$3.5B) is above analyst consensus, which supports recurring‑revenue momentum and may underpin near‑term revenue visibility. MarketBeat DOCU
• Neutral Sentiment: Zacks revised a number of quarterly EPS estimates upward (e.g., Q1 2027 to $0.36, Q2 2027 to $0.30, Q3 2027 to $0.42, Q4 2027 to $0.45; Q1–Q2 2028 also raised). These incremental changes suggest analysts are baking in steady improvement, but they are not large surprises. MarketBeat DOCU
• Neutral Sentiment: Coverage/attention: Zacks highlighted increased investor interest in DOCU in a recent article, which can amplify volatility around earnings and guidance events. Zacks: Investors Heavily Search DOCU
• Negative Sentiment: Zacks trimmed its Q3 2028 EPS estimate slightly (from $0.43 to $0.41). While modest, this downgrade injects some near‑term uncertainty and may temper enthusiasm from the broader upgrades. MarketBeat DOCU
• Negative Sentiment: Company EPS guidance was not clearly specified in the update (entries show revenue ranges but EPS fields blank), which can leave investors cautious until full guidance/disclosure is provided. MarketBeat DOCU

Docusign Company Profile

DocuSign, Inc (NASDAQ: DOCU) is a leading provider of electronic signature and digital transaction management solutions. The company’s flagship offering, DocuSign eSignature, enables organizations to send, sign and manage legally binding electronic agreements securely in the cloud. Beyond eSignature, DocuSign’s Agreement Cloud combines contract lifecycle management, document generation, and workflow automation to streamline agreement processes from initiation through execution and storage.

DocuSign’s platform serves a diverse customer base spanning industries such as finance, real estate, healthcare, technology, and government.